These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36184252)

  • 1. Probiotic supplementation induces remission and changes in the immunoglobulins and inflammatory response in active ulcerative colitis patients: A pilot, randomized, double-blind, placebo-controlled study.
    Agraib LM; Yamani MI; Tayyem R; Abu-Sneineh AT; Rayyan YM
    Clin Nutr ESPEN; 2022 Oct; 51():83-91. PubMed ID: 36184252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does probiotic supplementation improve quality of life in mild-to-moderately active ulcerative colitis patients in Jordan? A secondary outcome of the randomized, double-blind, placebo-controlled study.
    Rayyan YM; Agraib LM; Alkhatib B; Yamani MI; Abu-Sneineh AT; Tayyem RF
    Eur J Nutr; 2023 Oct; 62(7):3069-3077. PubMed ID: 37498369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial.
    Tamaki H; Nakase H; Inoue S; Kawanami C; Itani T; Ohana M; Kusaka T; Uose S; Hisatsune H; Tojo M; Noda T; Arasawa S; Izuta M; Kubo A; Ogawa C; Matsunaka T; Shibatouge M
    Dig Endosc; 2016 Jan; 28(1):67-74. PubMed ID: 26418574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.
    Tursi A; Brandimarte G; Papa A; Giglio A; Elisei W; Giorgetti GM; Forti G; Morini S; Hassan C; Pistoia MA; Modeo ME; Rodino' S; D'Amico T; Sebkova L; Sacca' N; Di Giulio E; Luzza F; Imeneo M; Larussa T; Di Rosa S; Annese V; Danese S; Gasbarrini A
    Am J Gastroenterol; 2010 Oct; 105(10):2218-27. PubMed ID: 20517305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
    Croft NM; Faubion WA; Kugathasan S; Kierkus J; Ruemmele FM; Shimizu T; Mostafa NM; Venetucci M; Finney-Hayward T; Sanchez Gonzalez Y; Bereswill M; Lazar A; Turner D
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):616-627. PubMed ID: 34153231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
    Miele E; Pascarella F; Giannetti E; Quaglietta L; Baldassano RN; Staiano A
    Am J Gastroenterol; 2009 Feb; 104(2):437-43. PubMed ID: 19174792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabis for the treatment of ulcerative colitis.
    Kafil TS; Nguyen TM; MacDonald JK; Chande N
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012954. PubMed ID: 30406638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial.
    Petersen AM; Mirsepasi H; Halkjær SI; Mortensen EM; Nordgaard-Lassen I; Krogfelt KA
    J Crohns Colitis; 2014 Nov; 8(11):1498-505. PubMed ID: 24972748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
    Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L
    Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probiotics for induction of remission in ulcerative colitis.
    Kaur L; Gordon M; Baines PA; Iheozor-Ejiofor Z; Sinopoulou V; Akobeng AK
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD005573. PubMed ID: 32128795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis.
    Sood A; Midha V; Makharia GK; Ahuja V; Singal D; Goswami P; Tandon RK
    Clin Gastroenterol Hepatol; 2009 Nov; 7(11):1202-9, 1209.e1. PubMed ID: 19631292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
    Atreya R; Peyrin-Biroulet L; Klymenko A; Augustyn M; Bakulin I; Slankamenac D; Miheller P; Gasbarrini A; Hébuterne X; Arnesson K; Knittel T; Kowalski J; Neurath MF; Sandborn WJ; Reinisch W;
    Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1063-1075. PubMed ID: 33031757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
    Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Potential Role of
    Pagnini C; Di Paolo MC; Urgesi R; Pallotta L; Fanello G; Graziani MG; Delle Fave G
    Microorganisms; 2023 May; 11(6):. PubMed ID: 37374884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial.
    Lang A; Salomon N; Wu JC; Kopylov U; Lahat A; Har-Noy O; Ching JY; Cheong PK; Avidan B; Gamus D; Kaimakliotis I; Eliakim R; Ng SC; Ben-Horin S
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1444-9.e1. PubMed ID: 25724700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study.
    Huynh HQ; deBruyn J; Guan L; Diaz H; Li M; Girgis S; Turner J; Fedorak R; Madsen K
    Inflamm Bowel Dis; 2009 May; 15(5):760-8. PubMed ID: 19067432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probiotics for induction of remission in ulcerative colitis.
    Mallon P; McKay D; Kirk S; Gardiner K
    Cochrane Database Syst Rev; 2007 Oct; (4):CD005573. PubMed ID: 17943867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Bioenhanced Curcumin With Mesalamine for Induction of Clinical and Endoscopic Remission in Mild-to-Moderate Ulcerative Colitis: A Randomized Double-Blind Placebo-controlled Pilot Study.
    Banerjee R; Pal P; Penmetsa A; Kathi P; Girish G; Goren I; Reddy DN
    J Clin Gastroenterol; 2021 Sep; 55(8):702-708. PubMed ID: 32889959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.
    Haifer C; Paramsothy S; Kaakoush NO; Saikal A; Ghaly S; Yang T; Luu LDW; Borody TJ; Leong RW
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):141-151. PubMed ID: 34863330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.